
Limb girdle muscular dystrophy (LGMD) is in fact not one single condition but a number of different inherited muscular dystrophies that are grouped under the label “limb girdle” because they generally affect the pelvic and shoulder girdles, causing weakness in the muscles in the top part of the arms and shoulders and the hips and thighs. These muscles are often called the “proximal” muscles because they are nearest to the body. The weakness usually affects the legs first, followed by the arms. It rarely affects the face. Some types of LGMD may also cause weakness in the “distal” muscles – those in the feet, ankles and calves, and the hands and wrists. A few specific types may cause heart problems or weakness of the breathing muscles.
Austria Belgium Bulgaria Canada (English) China China Croatia Denmark Egypt Georgia Germany India Latvia Mexico Netherlands New Zealand Poland Slovenia English Spain Sweden Turkey Turkey Turkey Czech Republic World Wide World Wide World Wide World WideRegistries for Limb Girdle Muscular Dystrophy
Current trials in LGMD
TREAT-NMD is working closely with the pharmaceutical companies planning trials in neuromuscular diseases. The resources and expertise available through the network can make it much easier for companies to do trials, and many of the doctors involved in the network are principal investigators for the trials that are currently ongoing.
Nevertheless, we cannot ourselves keep an up-to-date overview of all the trials that are currently happening across the world. The most comprehensive online listing of trials is at clinicaltrials.gov – companies are obliged to provide details of their trials there.
The table below lists all LGMD trials registered or updated on clinicaltrials.gov in the last 1000 days. Because it links directly to clinicaltrials.gov it is automatically updated whenever the information on clinicaltrials.gov changes.
Please note that TREAT-NMD can take no responsibility for the accuracy of the information below, which is pulled directly from clinicaltrials.gov.
- A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
- Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
- Trial Readiness and Endpoint Assessment in LGMD R1
- Evaluating Safety and Efficacy of Autologous Gene-edited Muscle Stem Cells (GenPHSats-bASKet)
- Limb-Girdle Video Assessment
- Defining Endpoints in Becker Muscular Dystrophy
- A Study to Evaluate the Safety of LION-101 in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
- GNT0006 Gene Therapy Trial in Patients With LGMDR9
- Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
- Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders
- A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China
- Study of BBP-418 in Patients With LGMD2I
- Motor Parameters in Patients With Limb Girdle Muscular Dystrophy
- Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E
- A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, and LGMD2C/R5, ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
Patient organisations
Canadian Neuromuscular Disease Registry – CNDR – Canada








Registry Publications - Summary Articles
Limb-girdle muscular dystrophies — international collaborations for translational research
Published : April, 2016